Lantheus to Present at the Wells Fargo Healthcare Conference
09/01/2022 - 08:30 AM
NORTH BILLERICA, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative diagnostics, targeted therapeutics and artificial intelligence solutions that empower clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Bob Marshall, Chief Financial Officer and Treasurer, and Paul Blanchfield, Chief Operating Officer, will present at the Wells Fargo Healthcare Conference at 8:00 a.m. ET on Thursday, September 8.
To access a live webcast of the presentation, please visit the Investors section of the Company’s website at www.lantheus.com . A replay of the webcast will be available on the Company’s website for at least 30 days following the live presentation.
About Lantheus With more than 60 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.
Contacts: Mark Kinarney Vice President, Investor Relations 978-671-8842 ir@lantheus.com
Melissa Downs Senior Director, Corporate Communications 646-975-2533 media@lantheus.com
LNTH Rankings
#2662 Ranked by Stock Gains
LNTH Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
North Billerica
About LNTH
lantheus holdings, inc. (nasdaq: lnth) is the parent company of lantheus medical imaging, inc. (lmi), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. lmi provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. lmi’s key products include the echocardiography contrast agent definity® vial for (perflutren lipid microsphere) injectable suspension; technelite® (technetium tc99m generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and xenon (xenon xe 133 gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. the company is headquartered in north billerica, massachusetts with offices in puerto rico and canada. for more information, visit www.lantheus.com.